KP1 for Health & Longevity

Created on 10/27/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

KP1, a laboratory-made fragment of Klotho, a protein whose levels fall with age, is studied to slow tissue scarring and sold only as a laboratory chemical. Mouse studies, nearly all from one research network, show it blocks the main scarring signal. No person has been documented to receive it, and no safety record or established dose exists. Risks are borrowed: skin tumors with another agent blocking that signal; contaminated supply. (Full Review)

Protocol

Published animal regimen, kidney models
1 mg/kg daily, intravenous
Study parameters for mice, not human doses
Why these figures do not convert
No defensible human figure
Data on how the body handles it and on tolerability are absent
Route
Injection
Intravenously or by implanted pump; oral administration is expected to fail
Time to effect
Time to effect
Unknown in humans
In mice, scarring markers shifted over one to eight weeks of daily dosing

Benefits

Contraindications
  • Anyone with an active or recently treated malignancy
  • People who are pregnant or breastfeeding
  • Anyone around the time of surgery or with unhealed wounds
  • People with disordered phosphate or calcium handling, including diagnosed hypophosphatemia or hyperparathyroidism
  • People with a history of multiple keratoacanthomas or cutaneous squamous-cell carcinoma
Key Interactions
Theoretical (inferred from mechanism)
  • Antifibrotic drugs (pirfenidone, nintedanib)
  • TGF-β-neutralizing antibodies and receptor kinase inhibitors (fresolimumab, galunisertib)
  • Renin-angiotensin blockers (lisinopril, losartan)
  • Corticosteroids and other immunosuppressants (prednisone, tacrolimus)
  • Checkpoint-inhibitor immunotherapy (pembrolizumab, nivolumab)
  • Over-the-counter anti-inflammatory medication (ibuprofen, naproxen)
  • Phosphate supplements and vitamin D (cholecalciferol, calcitriol)
  • Supplements with additive antifibrotic or TGF-β-lowering effects (curcumin, resveratrol)
  • Other interventions: sustained exercise training

Risk & Side Effects

  • High:
  • Medium:
  • Low: Tumors from blocking TGF-β; contaminated, mislabeled or absent product from unregulated sellers; mineral metabolism disturbance
  • Speculative: Impaired wound healing and tissue repair; immune reaction to an injected foreign peptide

Monitoring

Marker Target Why
Serum phosphorus 2.5–4.5 mg/dL Safety check: low phosphate with elevated Klotho
Serum calcium 8.6–10.2 mg/dL Safety check: same mineral disturbance
Intact parathyroid hormone (PTH) 15–65 pg/mL Safety check: overactive parathyroid with elevated Klotho
Estimated glomerular filtration rate (eGFR) Not specified in the ER Safety check: peptides clear through the kidney
Serum α-Klotho Not specified in the ER Expected to change: proposed indirect mechanism

Cadence: No established cadence; absent data, a reasonable schedule repeats the chemistry panel at four and twelve weeks, then every three to six months, with the skin examination annually or immediately on any new lesion.

Qualitative Assessment

  • New or changing skin lesions
  • Wound healing
  • Injection-site reactions
  • Energy, cognition and recovery